+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Neuronal Nicotinic Receptors. Pharmacology and Therapeutic Opportunities

  • ID: 2181038
  • Book
  • 422 Pages
  • John Wiley and Sons Ltd
1 of 3
Neuronal Nicotinic Receptors: Pharmacology and Therapeutic Opportunities

Edited by Stephen P. Arneric and Jorge D. Brioni

Nicotine′s efficacy in the treatment of pain and anxiolysis, and its usefulness as a memory enhancer, have been suspected for many years, but research into the molecular biology of nicotinic acetylcholine receptors (nAChRs) traditionally has focused on smoking cessation. Now, thanks to recent technological advances in the molecular biology and electrophysiology of nAChRs, an abundance of evidence has emerged in support of nAChR ligands in the treatment of a range of CNS disorders, including Alzheimer′s disease, Parkinson′s disease, neuropathic pain, attention deficit disorder, and depression.

Featuring contributions from an international team of experts in the field, this volume provides researchers and clinicians with a comprehensive review of nAChRs, their molecular biology, pharmacology, and clinical implications. Moving from the molecular to the clinical levels, the authors explore the latest developments in all areas of nAChR research, including:

  • Molecular biology and biochemistry of nAChRs
  • The physiological roles of nAChRs
  • Pharmacokinetics of nicotine–like alkaloids
  • Recent breakthroughs and emerging trends in nAChR medicinal chemistry
  • Current and emerging therapeutic applications of novel nAChR ligands.

A timely, authoritative review of basic research into nAChRs and their role in the development of new therapeutic strategies in the treatment of a range of various CNS diseases, Neuronal Nicotinic Receptors: Pharmacology and Therapeutic Opportunities is required reading for neuroscientists, pharmacologists, medicinal chemists, biological psychiatrists, and psychopharmacologists.

Note: Product cover images may vary from those shown
2 of 3

Purification and Cloning of Nicotinic Acetylcholine Receptors (J. Lindstrom).

Transcriptional Regulation of Neuronal Nicotinic Receptor Subunit Genes (D. Fornasari, et al.).

Molecular Composition and Biophysical Characteristics of Nicotinic Receptors (J. Ramirez–Latorre, et al.).

Desensitization and the Regulation of Neuronal Nicotinic Receptors (M. Marks).

Cell Lines as Models for Studies of Nicotinic Acetylcholine Receptors (R. Lukas).

Stable Expression of Human Neuronal Nicotinic Receptors (B. Buisson, et al.).


Functional Anatomy of Nicotinic Acetylcholine Receptors in Mammalian Brain (P. Clarke).

Nicotinic Receptor Modulation of Neurotransmitter Release (S. Kaiser & S. Wonnacott).

Functional Diversity of Nicotinic Acetylcholine Receptors in the Mammalian Central Nervous System: Physiological Relevance (E. Pereira, et al.).

Diverse Functions of Neuronal Nicotinic Receptors Determined by Subcellular Location (D. Berg, et al.).

Immunosuppressive and Anti–inflammatory Properties of Nicotine (M. Sopori).


Pharmacokinetics and Metabolism of Nicotine and Related Alkaloids (N. Benowitz & P. Jacob).

Nicotine and Related Compounds as PET and SPECT Ligands (V. Villemagne, et al).


Natural Products as a Source of Nicotinic Acetylcholine Receptor Modulators and Leads for Drug Discovery (M. Holladay, et al.).

Nicotinic Cholinergic Receptor Pharmacophores (R. Glennon & M. Dukat).


Neuronal Nicotinic Receptor Channel Dysfunction in a Human Epilepsy Syndrome (D. Bertrand & S. Berkovic).

The Role of Nicotine and Nicotinic Receptors in Psychopathology (S. Leonard, et al.).

Nicotine and Non–Nicotine Formulations for Smoking Cessation (S. Leischow & G. Cook).

Preclinical Evidence on the Neuroprotective Effects of Nicotinic Ligands (D. Donnelly–Roberts & J. Brioni).

Transdermal Nicotine Treatment of Attention Deficit Hyperactivity Disorder (E. Levin, et al.).

Neuronal Nicotinic Receptors: New Targets in the Treatment of Pain (C. Flores & K. Hargreaves).

Subtype–Selective nAChR Agonists for the Treatment of Neurological Disorders: SIB–1508Y and SIB–1553A (F. Menzaghi, et al.).

Nicotinic Acetylcholine Receptor–Targeted Compounds: A Summary of the Development Pipeline and Therapeutic Potential (M. Decker & S. Arneric).

Note: Product cover images may vary from those shown
3 of 3


4 of 3
Stephen P. Arneric
Jorge D. Brioni
Note: Product cover images may vary from those shown